Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
NCT04443062
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
58
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
177Lu-PSMA-617
Sponsor
Radboud University Medical Center
Collaborators
[object Object]
[object Object]